Axonics

AXNX · NASDAQ

$0.429−$0.0611 (−12.47%)TodayMarket closed ·
Prev close $0.4901

About AXNX

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.

Employees
797
Headquarters
Irvine, California
Listed
Oct 31, 2018
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

Axonics executives
NameTitleSince
Jonathan Monson—2024
Daniel Brennan——
Michael Mahoney——
Karen Noblett——
Vance Brown——

Revenue by product and region

Fiscal year ended Dec 31, 2022: $273.70M total revenue

By product

  • SNM net revenue$221.99M81.1%
  • Bulkamid net revenue$51.71M18.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Axonics suppliers and customers
CompanyRelationshipCorrelation
Alfred E. Mann Foundation For Scientific ResearchSupplier and customer—
Micro Systems Technologies Management AGSupplier and customer—

Similar companies

Companies in the same industry as Axonics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.